Imaging benzodiazepine receptors in man with [11C]suriclone by positron emission tomography.
Imaging benzodiazepine receptors in man with [11C]suriclone by positron emission tomography.
复制标题
通过正电子发射断层扫描使用[11C]舒立克隆对人体苯二氮卓受体进行成像。
DOI:
10.1016/0014-2999(86)90422-x
复制
发表时间:
1986
影响因子:
5
通讯作者:
Snyder,SH
中科院分区:
文献类型:
--
作者:
Frost,JJ;WagnerJr,HN;Dannals,RF;Ravert,HT;Wilson,AA;Links,JM;Rosenbaum,AE;Trifiletti,RR;Snyder,SH
Successful imaging by positron emission tomography (PET) of dopamine (Wagner et al., 1983) and opiate (Frost et al., 1985) receptors in man has depended in large part on the extremely high affinity (KD-0.1 nM) of the ligands,[11C] N-methylspiperone and [11C] carfentanil, for dopamine and opiate receptors respectively. PET imaging of receptors requires that almost all the radioligand in the brain be bound to receptors, a condition which is not fulfilled with ligands of lesser affinity. The benzodiazepine (BZD)-yaminobutyric acid (GABA) receptor complex has potential clinical importance, because GABA has been implicated in epilepsy, anxiety, and neurodegenerative disease.Flunitrazepam (FNZ), a potent BZD agonist, has been relatively unsuccessful as a ligand for in vivo binding studies. While at 0 C FNZ displays-1.0 nM KD for receptor sites, the affinity of FNZ and other BZDs decreases 10-fold at 37 C. The BZD antagonist Ro15-1788 is more potent in vitro at 0 C than FNZ, but also has ten times higher affinity at 0 as at 37 C;[HC] Ro15-1788 does provide PET images of BZD/GABA receptors in man and baboon (Hantraye et al., 1984; Persson et al., 1985).